Radiation Oncology Community Seeking Relief From an Emerging Crisis Under 2026 Changes to Medicare Coding and Reimbursement

Why It Matters

The cuts threaten the financial viability of community and freestanding radiation centers, especially in rural areas, risking reduced patient access to cancer care. Prompt policy action could stabilize the specialty and preserve essential oncology services.

Key Takeaways

• CMS 2026 rule revalued CPT 77402, 77407, 77412 codes.
• ASTRO reports >10% revenue drops for many practices.
• Providers face claim denials and delayed payments across payors.
• Congressional hearing urges HHS to intervene on reimbursement cuts.
• ASTRO seeks mid‑year CMS adjustments before 2027 rule.

Pulse Analysis

The Centers for Medicare & Medicaid Services (CMS) rolled out a sweeping overhaul of radiation oncology billing on Jan. 1, 2026, consolidating and revaluing the megavoltage external‑beam CPT codes 77402, 77407 and 77412. Intended to streamline reporting and align payments with contemporary technology costs, the final rule lowered the relative weight of these services across the hospital outpatient and physician fee schedules. While the technical rationale centers on cost containment, the abrupt reduction in relative value units has translated into immediate revenue shortfalls for providers who rely heavily on these high‑complexity treatments.

Early 2026 data confirm the financial shock. The American Society for Radiation Oncology (ASTRO) surveyed its members in March and found that a majority of respondents reported revenue declines exceeding 10 percent, with several practices indicating losses large enough to jeopardize operations. The impact is uneven: hospitals with mixed payer mixes absorb some losses, whereas freestanding cancer centers and rural physician groups—often dependent on Medicare and Medicaid—face the steepest cuts. Compounding the problem, insurers have begun denying or delaying claims tied to the newly defined codes, extending cash‑flow gaps and increasing administrative burdens.

Policymakers have responded quickly. In early April, Rep. John Joyce (R‑PA) raised the issue in a House Energy and Commerce subcommittee hearing, prompting HHS Secretary Robert F. Kennedy Jr. to pledge a review. Simultaneously, ASTRO submitted a formal letter to CMS Administrator Mehmet Oz requesting a mid‑year adjustment that would restore payment levels before the next scheduled rule change on Jan. 1, 2027. If CMS acts, it could avert practice closures and preserve access to radiation therapy in underserved markets; a delay, however, may accelerate consolidation and limit patient options, reshaping the oncology landscape.